Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα

被引:20
|
作者
Minniti, Elirosa [1 ,2 ]
Byl, Jo Ann W. [3 ]
Riccardi, Laura [2 ]
Sissi, Claudia [4 ]
Rosini, Michela [1 ]
De Vivo, Marco [2 ,5 ]
Minarini, Anna [1 ]
Osheroff, Neil [3 ,6 ,7 ]
机构
[1] Univ Bologna, Dept Pharm & Biotechnol, Alma Mater Studiorum, Via Belmeloro 6, I-40126 Bologna, Italy
[2] Ist Italiano Tecnol, Lab Mol Modeling & Drug Discovery, Via Morego 30, I-16163 Genoa, Italy
[3] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA
[4] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Via Marzolo 5, I-35131 Padua, Italy
[5] Forschungszentrum Julich, IAS INM Computat Biomed 5 9, Wilhelm Johnen Str, D-52428 Julich, Germany
[6] Vanderbilt Univ, Dept Med Hematol Oncol, Sch Med, Nashville, TN 37232 USA
[7] VA Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA
基金
美国国家卫生研究院;
关键词
Xanthone derivative; Polyamines; DNA topoisomerase II alpha; Anticancer drug; Catalytic inhibitor; DNA cleavage; POTENTIAL ANTICANCER DRUGS; DNA CLEAVAGE; DERIVATIVES; CANCER; TRANSPORT; F14512; DAMAGE; QUINOLONES; ETOPOSIDE; INSIGHTS;
D O I
10.1016/j.bmcl.2017.09.011
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
It has been proposed that xanthone derivatives with anticancer potential act as topoisomerase II inhibitors because they interfere with the ability of the enzyme to bind its ATP cofactor. In order to further characterize xanthone mechanism and generate compounds with potential as anticancer drugs, we synthesized a series of derivatives in which position 3 was substituted with different polyamine chains. As determined by DNA relaxation and decatenation assays, the resulting compounds are potent topoisomerase II alpha inhibitors. Although xanthone derivatives inhibit topoisomerase II alpha-catalyzed ATP hydrolysis, mechanistic studies indicate that they do not act at the ATPase site. Rather, they appear to function by blocking the ability of DNA to stimulate ATP hydrolysis. On the basis of activity, competition, and modeling studies, we propose that xanthones interact with the DNA cleavage/ligation active site of topoisomerase II alpha and inhibit the catalytic activity of the enzyme by interfering with the DNA strand passage step. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4687 / 4693
页数:7
相关论文
共 50 条
  • [21] Identification of potent catalytic inhibitors of human DNA topoisomerase II by structure-based virtual screening
    Dong, Guoqiang
    Wu, Ying
    Sun, Ying
    Liu, Na
    Wu, Shanchao
    Zhang, Wannian
    Sheng, Chunquan
    MEDCHEMCOMM, 2018, 9 (07) : 1142 - 1146
  • [22] Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II
    Xiong, Kai
    Qian, Chen
    Yuan, Yixian
    Wei, Lin
    Liao, Xinxing
    He, Liting
    Rees, Thomas W.
    Chen, Yu
    Wan, Jian
    Ji, Liangnian
    Chao, Hui
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2020, 59 (38) : 16631 - 16637
  • [23] Switch in Site of Inhibition: A Strategy for Structure-Based Discovery of Human Topoisomerase IIα Catalytic Inhibitors
    Baviskar, Ashish T.
    Amrutkar, Suyog M.
    Trivedi, Neha
    Chaudhary, Vikas
    Nayak, Anmada
    Guchhait, Sankar K.
    Banerjee, Uttam C.
    Bharatam, Prasad V.
    Kundu, Chanakya N.
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (04): : 481 - 485
  • [24] Novel aromatic-polyamine conjugates as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase
    Hong, Chen
    Luo, Wen
    Yao, Dong
    Su, Ya-Bin
    Zhang, Xin
    Tian, Run-Guo
    Wang, Chao-Jie
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (12) : 3213 - 3219
  • [25] Discovery of 1,2-diphenylethene derivatives as human DNA topoisomerase II catalytic inhibitors and antitumor agents
    Xu, Guangsen
    Li, Zhiying
    Ding, Yanjiao
    Shen, Yuemao
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 243
  • [26] Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase IIα inhibitors
    Legina, Maria S.
    Nogueira, Juan J.
    Kandioller, Wolfgang
    Jakupec, Michael A.
    Gonzalez, Leticia
    Keppler, Bernhard K.
    JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2020, 25 (03): : 451 - 465
  • [27] Identification of novel topoisomerase II alpha inhibitors by virtual screening, molecular docking, and bioassay
    Yu, Che
    Hu, Jiabao
    Luyten, Walter
    Sun, Dan
    Jiang, Tao
    CHEMICAL BIOLOGY & DRUG DESIGN, 2022, 99 (01) : 92 - 102
  • [28] Design, synthesis and biological evaluation of benzimidazole-rhodanine conjugates as potent topoisomerase II inhibitors
    Li, Penghui
    Zhang, Wenjin
    Jiang, Hong
    Li, Yongliang
    Dong, Changzhi
    Chen, Huixiong
    Zhang, Kun
    Du, Zhiyun
    MEDCHEMCOMM, 2018, 9 (07) : 1194 - 1205
  • [29] Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy
    Matias-Barrios, Victor M.
    Radaeva, Mariia
    Ho, Chia-Hao
    Lee, Joseph
    Adomat, Hans
    Lallous, Nada
    Cherkasov, Artem
    Dong, Xuesen
    CANCERS, 2021, 13 (15)
  • [30] Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle
    Sehested, M
    Jensen, PB
    BIOCHEMICAL PHARMACOLOGY, 1996, 51 (07) : 879 - 886